IDO1 and neoplasm: While enthusiasm for IDO inhibition combined with checkpoint inhibitors has diminished following failure in a metastatic melanoma phase 3 trial, alternate strategies could include targeting tryptophan metabolism, considering pathways that tumor cells may use to bypass IDO inhibition.